|| Checking for direct PDF access through Ovid
Triptans, 5-HT1B/1D receptors agonists, help maintain serotonin levels in the brain and therefore specifically target one of the major components in the migraine process. Sumatriptan was the first of these compounds to be developed and offered improved efficacy and tolerability over ergot-derived compounds. But the comparison of triptans proved to be particularly difficult. Direct comparative trials are clearly the best methods of evaluation of efficacy, tolerability and adverse effects of a clinician's capability of designing the proper therapy for the patient; but besides a scarcity of this type of data on the currently available compounds, a comparison among many trials was unable to estimate these parameters owing to dispersive data distribution of some 434 works considered. For this reason, we have deemed it right to establish a quick but exhaustive schedule type, merely in order to standardize all data obtained through a few fixed parameters and therefore directly comparable.